Last reviewed · How we verify
Gallium Ga 68-DOTATATE — Competitive Intelligence Brief
phase 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Gallium Ga 68-DOTATATE (Gallium Ga 68-DOTATATE) — Mayo Clinic. Gallium Ga 68-DOTATATE works by binding to specific targets in the body, allowing for diagnostic imaging.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gallium Ga 68-DOTATATE TARGET | Gallium Ga 68-DOTATATE | Mayo Clinic | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gallium Ga 68-DOTATATE CI watch — RSS
- Gallium Ga 68-DOTATATE CI watch — Atom
- Gallium Ga 68-DOTATATE CI watch — JSON
- Gallium Ga 68-DOTATATE alone — RSS
Cite this brief
Drug Landscape (2026). Gallium Ga 68-DOTATATE — Competitive Intelligence Brief. https://druglandscape.com/ci/gallium-ga-68-dotatate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing